U.S. Markets closed

Endocyte, Inc. (ECYT)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.47+0.02 (+0.82%)
At close: 4:00PM EDT
People also watch
ACRXINFIEPZMMACKCCXI

Endocyte, Inc.

3000 Kent Avenue
Suite A1-100
West Lafayette, IN 47906
United States
765-463-7175
http://www.endocyte.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees76

Key Executives

NameTitlePayExercisedAge
Mr. Michael A. ShermanChief Exec. Officer, Pres and Director545.98kN/A51
Dr. Philip S. Low Ph.D.Co-Founder, Chief Science Officer and DirectorN/AN/A69
Ms. Katherine K. ParkerVP of HR347.24kN/A52
Dr. Alison A. Armour M.B.,Ch.B., B.Sc., M.Sc., M.D., MRCP., FRCRChief Medical Officer460.7kN/A53
Dr. Christopher P. Leamon Ph.D.VP of R&D449.04k28.97k51
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company’s products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.

Corporate Governance

Endocyte, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 8. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.